Número total de visitas
| Visualizaciones | |
|---|---|
| CEMCAT ... | 909 |
Visitas al mes
| mayo 2025 | junio 2025 | julio 2025 | agosto 2025 | septiembre 2025 | octubre 2025 | noviembre 2025 | |
|---|---|---|---|---|---|---|---|
| CEMCAT ... | 8 | 10 | 76 | 5 | 73 | 20 | 338 |
Países con más visualizaciones
| Visualizaciones | |
|---|---|
| Estados Unidos | 524 |
| España | 178 |
| Brasil | 31 |
| China | 28 |
| Rusia | 20 |
| Singapur | 19 |
| Irlanda | 12 |
| Suecia | 10 |
| Francia | 7 |
| Japón | 6 |
Ciudades con más visualizaciones
| Visualizaciones | |
|---|---|
| Buffalo | 133 |
| Los Angeles | 123 |
| Barcelona | 107 |
| Dallas | 71 |
| St Louis | 58 |
| Ashburn | 21 |
| Singapore | 14 |
| Chandler | 12 |
| Dublin | 12 |
| Capellades | 10 |
Documentos más visitados
| Visualizaciones | |
|---|---|
| Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results | 720 |
| The potential of serum neurofilament as biomarker for multiple sclerosis | 622 |
| Retinal inner nuclear layer volume reflects inflammatory disease activity in multiple sclerosis: a longitudinal OCT study | 508 |
| Recomendaciones para la vacunación en pacientes con esclerosis múltiple candidatos a terapias inmunosupresoras: documento de consenso español | 462 |
| Traffic Lights Intervention Reduces Therapeutic Inertia: A Randomized Controlled Trial in Multiple Sclerosis Care | 408 |
| Oligoclonal bands increase the specificity of MRI criteria to predict multiple sclerosis in children with radiologically isolated syndrome | 392 |
| A R-Script for Generating Multiple Sclerosis Lesion Pattern Discrimination Plots | 384 |
| Adherence and satisfaction of smartphone- and smartwatch-based remote active testing and passive monitoring in people with multiple sclerosis: nonrandomized interventional feasibility study | 348 |
| Relationship between paramagnetic rim lesions and slowly expanding lesions in multiple sclerosis | 323 |
| Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis | 321 |



